Based on findings from a double-blind, placebo-controlled study evaluating its efficacy and safety, rituximab-arrx has received FDA approval for the treatment of patients with rheumatoid arthritis.
Search results for: biosimilars
Rheum After 5: Dr. Jonathan Kay, an Artist at Work
When Jonathan Kay, MD, attends a medical lecture, he does more than just listen to the speakers or watch their presentations. He typically whips out his pen and draws a caricature of someone in the room. Dr. Kay is a professor of medicine and holds the Timothy S. and Elaine L. Peterson Chair in Rheumatology…
Prior Authorization Is Under Review
I just couldn’t believe it. Like all of you, I receive many requests to see patients urgently. And like all of you, I can’t possibly accommodate all of those requests. So I triage: I look through the referrals and try to differentiate patients who want to be seen from those who need to be seen….
Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
The 2021 ACR Awards of Distinction & Distinguished Fellows
During ACR Convergence 2021 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care, announcing the recipients of the ACR’s 2021 Awards of Distinction, as well as the group of Distinguished Fellows. recognized for their contributions. Three pediatric rheumatologists and one pediatric fellow…
FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved
Cyltezo (adalimumab-adbm) may be interchanged for Humira (adalimumab) for all indications, according to an October decison by the FDA. The FDA has also approved a new combination of celecoxib and tramadol for pain management.
Psoriatic Arthritis Treatment Update
About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…
RheumPAC Advocacy Fund: Effecting Change
Professional practices, state societies and other organizations can support RheumPAC’s work with corporate funds through the RheumPAC Advocacy Fund.
Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions
As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.
High Cost of Specialty Drugs Demands Action
Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 32
- Next Page »